Evidence map›Paper›PMID 35211755›Full record

ArticleInternational journal of oncology2022

circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.

Yali Yu, Guixiang Dong, Zijun Li, Yan Zheng, Zhisong Shi, Guanghui Wang

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  7. Identification of TNFRSF1A as a potential biomarker for osteosarcoma.Cancer biomarkers : section A of Disease markers · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yali YuDepartment of Laboratory, Zhengzhou Orthopedic Hospital, Zhengzhou, Henan 450052, P.R. China.
Guixiang DongDepartment of Laboratory, Zhengzhou Orthopedic Hospital, Zhengzhou, Henan 450052, P.R. China.
Zijun LiDepartment of Laboratory, Zhengzhou Orthopedic Hospital, Zhengzhou, Henan 450052, P.R. China.
Yan ZhengDepartment of Laboratory, Zhengzhou Orthopedic Hospital, Zhengzhou, Henan 450052, P.R. China.
Zhisong ShiDepartment of Orthopedic Surgery, Zhumadian Central Hospital, Zhumadian, Henan 463000, P.R. China.
Guanghui WangDepartment of Orthopedic Surgery, Zhumadian Central Hospital, Zhumadian, Henan 463000, P.R. China.
Zhengzhou City Hospital · CNZhumadian Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA‑lipoprotein receptor 6 (circ‑LRP6) serves a role in promoting the tumorigenesis of retinoblastoma, esophageal squamous cell cancer and oral squamous cell carcinoma; however, whether circ‑LRP6 demonstrates the same effect in osteosarcoma (OS) is yet to be fully elucidated. The present study aimed to analyze the expression, role and potential molecular mechanism of circ‑LRP6 in OS. The expression levels of circ‑LRP6, microRNA (miR)‑141‑3p, histone deacetylase 4 (HDAC4) and high mobility group protein 1 (HMGB1) were evaluated by reverse transcription-quantitative PCR in OS tissues and cell lines. Cell Counting Kit‑8, Transwell and Matrigel assays were conducted to evaluate cell proliferation, migration and invasion, respectively. Western blotting was also performed to determine HDAC4 and HMGB1 protein expression levels. Bioinformatics and dual‑luciferase reporter assays were used to predict and analyze the interactions between circ‑LRP6 and miR‑141‑3p, miR‑141‑3p and HDAC4, as well as between miR‑141‑3p and HMGB1. Additionally, RNA immunoprecipitation was performed to verify the association between circ‑LRP6 and miR‑141‑3p. The results confirmed that circ‑LRP6 was highly expressed in OS tissues and cell lines. In addition, circ‑LRP6 negatively regulated the expression of miR‑141‑3p and, in turn, miR‑141‑3p negatively regulated HDAC4 and HMGB1 expression. Functional assays revealed that circ‑LRP6 knockdown inhibited the proliferation, migration and invasion of OS cells, whereas the inhibition of miR‑141‑3p or the overexpression of either HDAC4 or HMGB1 partly reversed the inhibitory effect of circ‑LRP6 knockdown. In summary, the present study determined that circ‑LRP6 knockdown inhibited the proliferation, migration and invasion of OS cells by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.

Indexed as

AdolescentAdultChildFemaleHistone DeacetylasesHMGB1 ProteinHumansLow Density Lipoprotein Receptor-Related Protein-6MaleMicroRNAsMiddle AgedOsteosarcomaRepressor ProteinsRNA, CircularHDAC4 protein, humanHistone DeacetylasesHMGB1 ProteinHMGB1 protein, humanLow Density Lipoprotein Receptor-Related Protein-6LRP6 protein, humanMicroRNAsMIRN142 microRNA, humanRepressor ProteinsRNA, Circularcircular RNA‑lipoprotein receptor 6high mobility group protein 1histone deacetylase 4microRNA-141‑3posteosarcoma

Identifiers

PMID35211755
PMCPMC8878724
OpenAlexW4212825434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.